Physician profile
Jose Moreno
NPI 1699768184
$8,232.25
in general payments reported to CMS, 2019-2025
52 companies · $1,696 in 2025
The $1,696 reported for 2025 was more than what 76% of Urology providers received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,858 · 2020: $872 · 2021: $684 · 2022: $933 · 2023: $693 · 2024: $1,498 · 2025: $1,696.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,887.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,886.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $881.47 | 2019-2025 | |
| Dendreon Pharmaceuticals LLC | $761.35 | 2019-2025 | Provenge |
| Janssen Scientific Affairs, LLC | $665.96 | 2021-2025 | Erleada |
| Ferring Pharmaceuticals INC. | $574.49 | 2019-2025 | Adstiladrin |
| Procept Biorobotics Corporation | $379.32 | 2023-2025 | Aquabeam Robotic System, Aquabeam System |
| Janssen Biotech, INC. | $355.08 | 2019-2025 | Erleada, Akeega |
| Medtronic, INC. | $344.76 | 2022-2025 | Interstim |
| Pfizer INC. | $339.94 | 2019-2025 | |
| Astellas Pharma US INC | $332.89 | 2019-2025 | Xtandi, Myrbetriq, Veozah |
| Endo Pharmaceuticals INC. | $280.99 | 2019-2023 | Xiaflex |
| Abbvie INC. | $274.34 | 2019-2025 | |
| Teleflex LLC | $267.62 | 2021-2025 | Barrigel, Urolift |
| Boston Scientific Corporation | $209.77 | 2019-2025 | Rezum Generator, Axonics, Spaceoar System |
| Coloplast Corp | $209.54 | 2019-2022 | |
| Myovant Sciences INC. | $198.17 | 2021-2022 |
Show all 50 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic USA, INC. | $187.82 | 2020 | |
| Sumitomo Pharma America, INC. | $165.03 | 2023-2025 | Gemtesa, Orgovyx |
| Intuitive Surgical, INC. | $130.00 | 2025 | |
| Blue Earth Diagnostics | $126.95 | 2019-2023 | |
| Novartis Pharmaceuticals Corporation | $121.09 | 2024-2025 | |
| Bioprotect Medical, INC. | $119.05 | 2024-2025 | Bioprotect Balloon Implant System |
| Urogen Pharma, INC. | $115.67 | 2021-2025 | |
| Antares Pharma, INC. | $107.84 | 2022-2025 | Xyosted |
| Merck Sharp & Dohme LLC | $97.51 | 2019-2024 | Keytruda, Lynparza |
| Axonics, INC. | $93.26 | 2021-2024 | Axonics, Bulkamid |
| Endo USA, INC. | $87.09 | 2024-2025 | Xiaflex |
| Sun Pharmaceutical Industries INC. | $79.00 | 2019-2024 | |
| E.R. Squibb & Sons, L.L.C. | $74.55 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $67.89 | 2019-2024 | Lynparza |
| C. R. Bard, INC. & Subsidiaries | $58.98 | 2021-2023 | Bard Urinary Drainage Bag |
| Olympus America INC. | $54.32 | 2022-2025 | Itind System, Cysto-Nephro Videoscope |
| Foundation Medicine, INC. | $42.86 | 2020-2022 | |
| Amgen INC. | $40.23 | 2019-2020 | |
| Accord Healthcare, INC. | $38.62 | 2023 | |
| Neotract INC. | $35.69 | 2019-2020 | |
| Zyla Life Sciences, INC. | $30.13 | 2020 | |
| Allergan, INC. | $29.32 | 2020-2022 | |
| Ambu INC. | $29.10 | 2021 | |
| Aytu Biopharma, INC. | $27.74 | 2019 | |
| Halozyme INC | $24.50 | 2023 | |
| Tolmar, INC. | $21.66 | 2024 | |
| Avadel Specialty Pharmaceuticals, LLC | $20.54 | 2019 | |
| Immunitybio, INC. | $20.12 | 2025 | |
| Tolmar Pharmaceuticals, INC. | $17.90 | 2019 | |
| Davol INC. | $17.77 | 2021 | |
| Clarus Therapeutics INC. | $17.33 | 2021 | |
| Baxter Healthcare | $17.31 | 2020 | |
| Dentsply Ih INC. | $14.65 | 2019 | |
| Urovant Sciences INC | $12.89 | 2022 | |
| Mission Pharmacal Company | $12.15 | 2019 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jose Moreno listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.